FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT (OF CHANGES IN	BENEFICIAL	OWNERSHIP
-------------	---------------	------------	------------------

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cochran John				2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST]						(Che	eck all applic Director	,		on(s) to Issu 10% Ow Other (s	mer		
(Last) C/O AQU	,	irst) ΓHERAPEUTIC	(Middle) S, INC.		3. Date of Earliest Transaction (Month/Day/Year) 06/22/2022						below) below)						
30 TECHNOLOGY DRIVE					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WARRE	N N	J	07059							- 1	X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			2. Transac Date (Month/Da	Execution Date,		Code (Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)			ed (A) or tr. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	Formally (D) of (I) (In		Direct Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			mstr. 4)	
Common Stock											99,486			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date (Month/Day/Year) if any		Cod	Transaction of Code (Instr. Derivative		ive ies ed ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Cod	e V	(A)		Date Exercisabl		Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Purchase)	\$0.7132	06/22/2022		A		25,000		06/22/2023	(1)	06/22/2032	Common Stock	25,000	\$0	25,000)	D	

Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date.

Remarks:

/s/ Lori Braender, as Attorney-06/24/2022 In-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.